Neumora Therapeutics, Inc. Stock

Equities

NMRA

US6409791000

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-24 EDT 5-day change 1st Jan Change
9.17 USD -1.50% Intraday chart for Neumora Therapeutics, Inc. -5.17% -46.22%
Sales 2024 * - Sales 2025 * - Capitalization 1.46B 2B
Net income 2024 * -237M -324M Net income 2025 * -271M -370M EV / Sales 2024 * -
Net cash position 2024 * 478M 653M Net cash position 2025 * 693M 947M EV / Sales 2025 * -
P/E ratio 2024 *
-6.19 x
P/E ratio 2025 *
-5.85 x
Employees 120
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.92%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.50%
1 week-5.17%
Current month+0.88%
1 month+0.22%
3 months-50.54%
6 months-23.07%
Current year-46.22%
More quotes
1 week
8.95
Extreme 8.95
9.81
1 month
8.84
Extreme 8.84
10.15
Current year
8.82
Extreme 8.82
21.00
1 year
8.82
Extreme 8.82
21.00
3 years
8.82
Extreme 8.82
21.00
5 years
8.82
Extreme 8.82
21.00
10 years
8.82
Extreme 8.82
21.00
More quotes
Managers TitleAgeSince
Founder 33 19-10-31
Chief Executive Officer 51 23-07-17
Founder 57 19-10-31
Members of the board TitleAgeSince
Founder 57 19-10-31
Director/Board Member 71 21-03-31
Director/Board Member 50 19-12-31
More insiders
Date Price Change Volume
24-05-24 9.17 -1.50% 285,744
24-05-23 9.31 -3.52% 570,506
24-05-22 9.65 +2.12% 596,126
24-05-21 9.45 -2.48% 374,068
24-05-20 9.69 +0.21% 325,671

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm

More quotes
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.17 USD
Average target price
23.84 USD
Spread / Average Target
+160.00%
Consensus